HC Wainwright Issues Optimistic Forecast for Curis Earnings

Curis, Inc. (NASDAQ:CRIS) – Equities researchers at HC Wainwright raised their Q2 2026 earnings estimates for Curis in a report issued on Friday, July 24th. HC Wainwright analyst S. Nik now forecasts that the biotechnology company will earn ($5.70) per share for the quarter, up from their previous estimate of ($5.80). HC Wainwright currently has a “Buy” rating and a $43.00 target price on the stock. The consensus estimate for Curis’ current full-year earnings is ($25.50) per share. HC Wainwright also issued estimates for Curis’ Q3 2026 earnings at ($5.87) EPS, Q4 2026 earnings at ($6.04) EPS, FY2026 earnings at ($33.78) EPS and FY2027 earnings at ($26.53) EPS.

CRIS has been the topic of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Zacks Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $43.00.

Curis Trading Down 4.1%

Curis stock opened at $4.69 on Tuesday. The company has a market capitalization of $9.15 million, a PE ratio of -0.20 and a beta of 3.08. Curis has a 12 month low of $3.61 and a 12 month high of $39.00. The stock has a 50-day moving average price of $7.59 and a two-hundred day moving average price of $13.11.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share for the quarter, missing the consensus estimate of ($6.53) by ($18.47).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CRIS. Jane Street Group LLC grew its position in shares of Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 10,586 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Curis during the fourth quarter worth about $26,000. Focused Wealth Management Inc lifted its stake in shares of Curis by 83.4% in the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 49,900 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Curis by 52.2% in the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 125,823 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.